Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ekaterina I Ryabova"'
Autor:
Ilias B. Esmagambetov, Ekaterina I. Ryabova, Artem A. Derkaev, Dmitry V. Shcheblyakov, Inna V. Dolzhikova, Irina A. Favorskaya, Daria M. Grousova, Mikhail A. Dovgiy, Vladimir V. Prokofiev, Andrey I. Gosudarev, Daria V. Byrikhina, Ilia D. Zorkov, Anna A. Iliukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionNumerous agents for prophylaxis of SARS-CoV-2-induced diseases are currently registered for the clinical use. Formation of the immunity happens within several weeks following vaccine administration which is their key disadvantage. In cont
Externí odkaz:
https://doaj.org/article/435734489115452892c1fe539af6307b
Autor:
Artem A. Derkaev, Ekaterina I. Ryabova, Ilias B. Esmagambetov, Dmitry V. Shcheblyakov, Svetlana A. Godakova, Irina D. Vinogradova, Anatoly N. Noskov, Denis Y. Logunov, Boris S. Naroditsky, Alexander L. Gintsburg
Publikováno v:
Frontiers in Microbiology, Vol 13 (2022)
Botulinum neurotoxin (BoNT) is one of the most dangerous bacterial toxins and a potential biological weapon component. BoNT mechanism of pathological action is based on inhibiting the release of neurotransmitters from nerve endings. To date, anti-BoN
Externí odkaz:
https://doaj.org/article/c0bb6cd09f8842ffbbc0ca9938c87bb4
Autor:
Irina A. Favorskaya, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Inna V. Dolzhikova, Irina A. Alekseeva, Anastasia I. Korobkova, Daria V. Voronina, Ekaterina I. Ryabova, Artem A. Derkaev, Anna V. Kovyrshina, Anna A. Iliukhina, Andrey G. Botikov, Olga L. Voronina, Daria A. Egorova, Olga V. Zubkova, Natalia N. Ryzhova, Ekaterina I. Aksenova, Marina S. Kunda, Denis Y. Logunov, Boris S. Naroditsky, Alexandr L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibod
Externí odkaz:
https://doaj.org/article/f07abc82d4394ceda24adf1504e604ad
Autor:
Ilias B. Esmagambetov, Dmitriy V. Shcheblyakov, Daria A. Egorova, Olga L. Voronina, Artem A. Derkaev, Daria V. Voronina, Olga Popova, Ekaterina I. Ryabova, Dmitriy N. Shcherbinin, Ekaterina I. Aksenova, Andrey N. Semenov, Marina S. Kunda, Natalia N. Ryzhova, Olga V. Zubkova, Amir I. Tukhvatulin, Denis Yu. Logunov, Boris S. Naroditsky, Sergey V. Borisevich, Alexander L. Gintsburg
Publikováno v:
Acta Naturae
Ebola fever is an acute, highly contagious viral disease with a mortality rate that can reach 90%. There are currently no licensed therapeutic agents specific to Ebola in the world. Monoclonal antibodies (MAbs) with viral-neutralizing activity and hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2153c3a8f3ff59d5471c7a9d31774bd
https://doi.org/10.32607/actanaturae.11487
https://doi.org/10.32607/actanaturae.11487
Autor:
Z. M. Galushkina, N V Strukova, Ekaterina A. Romanovskaya-Romanko, N. B. Polyakov, A M Lyaschuk, Andrey I. Solovyev, A. V. Gromov, Tatyana N. Bolshakova, Igor V. Krasilnikov, Anna S. Karyagina, Vladimir G. Lunin, Marina E. Subbotina, T. M. Grunina, Lyubov’ A. Soboleva, Vladimir V. Prokofiev, A. V. Grishin, Ekaterina I. Ryabova, Maria S. Generalova, Vladimir G. Zhukhovitsky, Olga Yu. Dobrinina, Daniil A. Grumov
Publikováno v:
Biochemistry. Biokhimiia
A new platform for creating anti-coronavirus epitope vaccines has been developed. Two loop-like epitopes with lengths of 22 and 42 amino acid residues were selected from the receptor-binding motif of the Spike protein from the SARS‑CoV‑2 virus th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30eec3e708c9539227b5e18b221d1ef5
http://europepmc.org/articles/PMC8527442
http://europepmc.org/articles/PMC8527442
Autor:
Ekaterina I Ryabova, Dmitry V. Shcheblyakov, Denis Y. Logunov, Andrey G Botikov, Alexandr L. Gintsburg, Irina A Alekseeva, Ekaterina I. Aksenova, Irina A Favorskaya, Olga L. Voronina, Artem A Derkaev, Natalia N. Ryzhova, Boris S. Naroditsky, M.S. Kunda, Anna V. Kovyrshina, Ilias B Esmagambetov, Daria V Voronina, Daria A. Egorova, Inna V. Dolzhikova, Anna A. Iliukhina, Anastasia I Korobkova, Olga V. Zubkova
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::953137976c48f1113918d4e21bcf2bb8
https://doi.org/10.1101/2021.11.24.469842
https://doi.org/10.1101/2021.11.24.469842
